此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

在房颤消融术后开始阻塞性睡眠呼吸暂停患者的CPAP治疗 (STOP-AFib)

2026年9月30日 更新者:Beijing Anzhen Hospital

心房颤动消融后阻塞性睡眠呼吸暂停患者开始CPAP治疗:一项多中心、开放标签、随机临床试验

Atrial fibrillation (AF) is one of the most common clinical arrhythmias. Catheter ablation is an effective therapeutic strategy; however, recurrence rates remain substantial, ranging from 20% to 45%. Previous studies have established a strong association between obstructive sleep apnea (OSA) and the risk of AF recurrence following ablation. While continuous positive airway pressure (CPAP) is the standard intervention for OSA, and some observational studies suggest it may reduce post-ablation recurrence in patients with comorbid OSA, small randomized controlled trials have failed to confirm a clear benefit, potentially due to poor adherence.

This study aims to evaluate the clinical benefit of post-ablation CPAP therapy in AF patients with comorbid OSA.

Participants will:

  • Be randomly assigned to either the CPAP group or the usual care group.
  • If in the CPAP group, use a CPAP device for 12 months.
  • Wear an ambulatory ECG recorder for a 7-day period at 3, 6, 9, and 12 months after randomization.
  • Complete follow-up checkups either at the clinic or over the phone at 1, 3, 6, and 12 months after randomization.

研究概览

详细说明

Atrial fibrillation (AF) is a common sustained cardiac arrhythmia, with recurrence rates of 20-45% after catheter ablation. Obstructive sleep apnea (OSA) is a common comorbidity and an important modifiable risk factor for post-ablation AF recurrence. Continuous positive airway pressure (CPAP) is the standard therapy for OSA, but its effect on reducing AF recurrence after ablation remains uncertain.This study aims to evaluate whether, in patients with OSA and AF who undergo catheter ablation, the postoperative CPAP treatment can increase the rate of no recurrence of atrial arrhythmia within one year compared to usual treatment. This prospective, multicenter, open-label, parallel-group randomized controlled trial will be conducted at approximately 20 centers in mainland China. Approximately 658 adults aged 18-75 years with persistent AF and diagnosed OSA who have successfully undergone first-time catheter ablation will be enrolled.

After confirmation of eligibility and informed consent, participants will be randomized in a 1:1 ratio to receive either CPAP therapy plus usual care or usual care alone. CPAP therapy will be provided for 12 months, with treatment parameters determined by pressure titration, and adherence monitored using device-recorded data. Participants in the usual care group will receive standard AF management and standardized education regarding OSA; additional OSA treatments outside the study protocol will be permitted and documented.All participants will receive guideline-directed medical therapy for AF.

Follow-up will last at least 12 months, with assessments at approximately 1, 3, 6, and 12 months after randomization. Atrial arrhythmia monitoring will be performed primarily using ambulatory ECG recorders.

The primary outcome is freedom from atrial arrhythmia recurrence within 12 months after randomization. Secondary outcomes include atrial arrhythmia recurrence patterns, arrhythmia-related interventions, atrial fibrillation burden, and changes in quality-of-life and psychological assessment scores.

研究类型

介入性

注册 (估计的)

658

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Tianjin、中国
        • 尚未招聘
        • Tianjin Medical University Second Hospital
        • 首席研究员:
          • Xiaoyun Zhao, Professor
        • 接触:
    • Beijing Municipality
      • Beijing、Beijing Municipality、中国、100029
        • 招聘中
        • Beijing Anzhen Hospital
        • 接触:
        • 首席研究员:
          • Jiang Xie, Professor
        • 首席研究员:
          • Shaoping Nie, Professor
        • 首席研究员:
          • Deyong Long, Professor
      • Beijing、Beijing Municipality、中国、100730
        • 尚未招聘
        • Beijing Hospital
        • 接触:
        • 首席研究员:
          • Wei Gong, Professor
      • Beijing、Beijing Municipality、中国、102206
        • 尚未招聘
        • Peking University International Hospital
        • 接触:
        • 首席研究员:
          • Yanwen Jiang, Professor
      • Beijing、Beijing Municipality、中国、100020
        • 尚未招聘
        • Beijing Chaoyang Hospital, Capital Medical University
        • 接触:
          • Zhiling Zhao, Professor
          • 电话号码:+86-10-85231000
          • 邮箱:cysleep@163.com
        • 首席研究员:
          • Zhiling Zhao, Professor
      • Beijing、Beijing Municipality、中国、100035
        • 尚未招聘
        • Beijing Jishuitan Hospital
        • 接触:
        • 首席研究员:
          • Yang Cheng, Professor
    • Fujian
      • Fuzhou、Fujian、中国、350001
        • 尚未招聘
        • Fujian Medical University Union Hospital
        • 接触:
        • 首席研究员:
          • Xiangqi Chen, Professor
      • Fuzhou、Fujian、中国、350004
        • 尚未招聘
        • First Affiliated Hospital of Fujian Medical University
        • 接触:
          • Ningfang Lian, Professor
          • 电话号码:+86 059187981698
          • 邮箱:1533532863@qq.com
        • 首席研究员:
          • Ningfang Lian, Professor
      • Zhangzhou、Fujian、中国、363000
        • 尚未招聘
        • Zhangzhou Hospital of Fujian Province
        • 接触:
        • 首席研究员:
          • Li Lin, Professor
    • Guangxi
      • Nanning、Guangxi、中国、530021
        • 尚未招聘
        • People's Hospital of Guangxi Zhuang Autonomous Region
        • 接触:
        • 首席研究员:
          • Mingming Zhao, Professor
    • Hebei
      • Langfang、Hebei、中国、065000
        • 尚未招聘
        • Langfang People's Hospital
        • 接触:
        • 首席研究员:
          • Zengming Xue, Professor
      • Shijiazhuang、Hebei、中国、050000
        • 招聘中
        • Shijiazhuang Great Wall Hospital of Integrated Traditional Chinese and Western Medicine
        • 接触:
          • Linyi Huang, Professor
          • 电话号码:+86-0311-85837801
          • 邮箱:496777551@qq.com
        • 首席研究员:
          • Linyi Huang, Professor
      • Xingtai、Hebei、中国、055250
        • 招聘中
        • The Ninth Hospital of Xingtai
        • 接触:
        • 首席研究员:
          • Zhanwei Liu, Professor
    • Heilongjiang
      • Harbin、Heilongjiang、中国、150086
        • 尚未招聘
        • Second Affiliated Hospital of Harbin Medical University
        • 接触:
        • 首席研究员:
          • Wei Meng, Professor
    • Henan
      • Shangqiu、Henan、中国
        • 尚未招聘
        • Shangqiu First People's Hospital
        • 接触:
        • 首席研究员:
          • Renshan Niu, Professor
      • Zhengzhou、Henan、中国、450052
        • 尚未招聘
        • The First Affiliated Hospital of Zhengzhou University
        • 接触:
        • 首席研究员:
          • Gangqiong Liu, Professor
    • Hubei
      • Wuhan、Hubei、中国、430014
        • 尚未招聘
        • Wuhan No. 1 Hospital
        • 接触:
          • Zhihua Yu, Professor
          • 电话号码:+86 02785332144
          • 邮箱:whyu027@163.com
        • 首席研究员:
          • Zhihua Yu, Professor
      • Wuhan、Hubei、中国、430056
        • 尚未招聘
        • Wuhan Asia General Hospital
        • 接触:
        • 首席研究员:
          • Ning Man, Professor
    • Hunan
      • Changsha、Hunan、中国、410011
        • 尚未招聘
        • The Second Xiangya Hospital of Central South University
        • 接触:
        • 首席研究员:
          • Ruoyun Ouyang, Professor
    • Jiangsu
      • Nanjing、Jiangsu、中国、210029
        • 尚未招聘
        • The First Affiliated Hospital of Nanjing Medical University
        • 接触:
        • 首席研究员:
          • Ning Ding, Professor
    • Jilin
      • Changchun、Jilin、中国、130021
        • 尚未招聘
        • The First Hospital of Jilin University
        • 接触:
          • Haibo Yuan, Professor
          • 电话号码:+86-431-88782222
          • 邮箱:hyuan@jlu.edu.cn
        • 首席研究员:
          • Haibo Yuan, Professor
    • Liaoning
      • Dalian、Liaoning、中国、116011
        • 尚未招聘
        • First Affiliated Hospital of Dalian Medical University
        • 接触:
        • 首席研究员:
          • Haiying Tang, Professor
      • Shenyang、Liaoning、中国、110004
        • 尚未招聘
        • Shengjing Hospital of China Medical University
        • 接触:
        • 首席研究员:
          • Li Xiao, Professor
      • Shenyang、Liaoning、中国、110001
        • 尚未招聘
        • First Affiliated Hospital of China Medical University
        • 接触:
        • 首席研究员:
          • Wenyang Li, Professor
    • Shandong
      • Dongying、Shandong、中国、257034
        • 尚未招聘
        • Shengli Oilfield Central Hospital
        • 接触:
        • 首席研究员:
          • Xiangfei Liu, Professor
      • Linyi、Shandong、中国、276003
        • 尚未招聘
        • Linyi People's Hospital
        • 接触:
        • 首席研究员:
          • Li Wei, Professor
    • Shanxi
      • Taiyuan、Shanxi、中国、030001
        • 尚未招聘
        • Second Hospital of Shanxi Medical University
        • 接触:
        • 首席研究员:
          • Xiaoling Gao, Professor
    • Tianjin Municipality
      • Tianjin、Tianjin Municipality、中国、300222
        • 尚未招聘
        • Tianjin Chest Hospital
        • 接触:
        • 首席研究员:
          • Fang Zhao, Professor
    • Yunnan
      • Kunming、Yunnan、中国
        • 尚未招聘
        • Yan'an Hospital of Kunming City
        • 接触:
          • Xia Jiang, Professor
          • 电话号码:+86-0871-63211073
          • 邮箱:378972370@qq.com
        • 首席研究员:
          • Xia Jiang, Professor
    • Zhejiang
      • Ningbo、Zhejiang、中国、315010
        • 尚未招聘
        • First Affiliated Hospital of Ningbo University
        • 接触:
        • 首席研究员:
          • Maoqing Tong, Professor

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

Patients must meet all of the following conditions to be eligible for the study:

  • Age 18-75 years.
  • Patients with persistent AF who received catheter ablation for the first time.
  • Diagnosed with OSA.
  • Able to tolerate CPAP therapy.
  • Capable of understanding and complying with the study protocol.
  • Willing to sign the informed consent form.

Exclusion Criteria:

Patients meeting any of the following criteria will be excluded from the study:

  • Secondary AF.
  • Left atrial anteroposterior diameter 60mm (measured via parasternal long-axis view).
  • Left ventricular ejection fraction < 30%.
  • Comorbid moderate-to-severe mitral stenosis or history of prosthetic valve replacement (mechanical or bioprosthetic).
  • Pregnant or breastfeeding women.
  • History of myocardial infarction, percutaneous coronary intervention, or cardiac surgery within 3 months prior to screening.
  • History of stroke or transient ischemic attack within 6 months prior to screening.
  • Perioperative complications related to the ablation procedure occurring prior to randomization.
  • Inability to discontinue antiarrhythmic drugs (AADs) post-procedure due to other reasons.
  • Life expectancy < 1 year.
  • Central sleep apnea.
  • Conditions requiring ventilatory support, including obesity hypoventilation syndrome (defined as BMI > 30kg/m² and awake PaCO₂ > 45mmHg), amyotrophic lateral sclerosis, or chronic obstructive pulmonary disease with > 1 episode of respiratory failure or hypercapnia.
  • Treatment-emergent central sleep apnea during CPAP tolerance assessment that cannot be corrected prior to randomization.
  • Receipt of instrumental or surgical treatment for OSA within 3 months prior to screening, including CPAP, oral appliances, ENT surgery, or bariatric surgery.
  • Use of glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide receptor agonists, or glucagon receptor agonists for weight loss within 3 months prior to screening, or plans to initiate such medications within the next year.
  • Current participation in other drug or device trials.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:CPAP Group

Usual care combined with CPAP therapy.

Participants receive CPAP therapy provided by the research team. Treatment parameters are determined following auto-titrating or manual pressure titration. Prior to treatment initiation, participants receive training on device usage, mask fitting and adjustment, equipment cleaning and maintenance, and data transmission methods. Study physicians and technicians provide support to address any CPAP-related discomfort. 'Good adherence' is defined as device usage of ≥ 4 hours per night on ≥ 70% of days.

Participants receive standardized medical therapy for atrial fibrillation in accordance with international guidelines and clinical routine. For OSA management, researchers provide standardized health education. This includes informing participants about the risks associated with OSA and advising on lifestyle modifications, including weight loss, adopting a lateral sleeping position, and avoiding alcohol and sedatives.

有源比较器:Usual Care Group

Standard of care for atrial fibrillation and usual care for OSA (health education). Researchers advise participants to visit sleep centers or pulmonology departments for further assessment/treatment at their own discretion, but do not intervene in their choice of OSA therapy or provide the study CPAP device.

Participants receive standardized medical therapy for atrial fibrillation in accordance with international guidelines and clinical routine. For OSA management, researchers provide standardized health education. This includes informing participants about the risks associated with OSA and advising on lifestyle modifications, including weight loss, adopting a lateral sleeping position, and avoiding alcohol and sedatives.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of freedom from atrial arrhythmia recurrence.
大体时间:Within 12 months

Recurrence is defined as a composite of:

  1. Any documented atrial arrhythmia (AF / Atrial Tachycardia [AT] / Atrial Flutter [AFL]) lasting 30 seconds after a 3-month blanking period;
  2. Use of Class I or III AADs after the 3-month blanking period;
  3. Cardioversion performed after the 3-month blanking period;
  4. Repeat catheter ablation performed at any time.
Within 12 months

次要结果测量

结果测量
措施说明
大体时间
任何记录在案的持续时间≥30秒的房性心律失常(AF/AFL/AT)的发生率。
大体时间:在12个月内(经过3个月的空白期后)。
在12个月内(经过3个月的空白期后)。
记录在案的持续≥30秒的房颤发生率。
大体时间:在12个月内(经过3个月的空白期后)。
在12个月内(经过3个月的空白期后)。
记录在案且持续≥30秒的AT的发生率。
大体时间:在12个月内(经过3个月空白期后)。
在12个月内(经过3个月空白期后)。
记录到的持续≥30秒的房扑(AFL)发生率。
大体时间:12个月内(经过3个月空白期后)。
12个月内(经过3个月空白期后)。
使用Ⅰ类或Ⅲ类抗心律失常药物的患者比例。
大体时间:12个月内(经过3个月空白期后)。
12个月内(经过3个月空白期后)。
接受心脏复律的患者比例。
大体时间:12个月内(经过3个月空白期后)。
12个月内(经过3个月空白期后)。
接受重复导管消融术的患者比例。
大体时间:在12个月内。
在12个月内。
AF负荷
大体时间:在12个月内。
在12个月内。
Change in quality of life assessed by the Atrial Fibrillation Effect on Quality-of-Life questionnaire.
大体时间:Baseline, Month 12.

Scores range from 0 to 100, where higher scores indicate a better quality of life.

Baseline, Month 12.
Change in anxiety and depression assessed by the Hospital Anxiety and Depression Scale.
大体时间:Baseline, Month 12.

Scores for both the anxiety and depression subscales range from 0 to 21, where higher scores indicate worse anxiety and depression.

Baseline, Month 12.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月12日

初级完成 (估计的)

2029年1月31日

研究完成 (估计的)

2029年1月31日

研究注册日期

首次提交

2026年2月25日

首先提交符合 QC 标准的

2026年2月25日

首次发布 (实际的)

2026年3月2日

研究记录更新

最后更新发布 (实际的)

2026年10月5日

上次提交的符合 QC 标准的更新

2026年9月30日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅